INTRODUCTION
============

Mesial temporal lobe epilepsy (mTLE) is the most common form of epilepsy of adulthood. In mTLE an initial "epileptogenic event" (head trauma, stroke, brain infection or tumor) is often identifiable which is followed, after a latent period of weeks to years, by the spontaneous occurrence of seizures. Multiple pathological and physio-pathological alterations have been identified that may be responsible for the transformation of a normal brain in an epileptic one ([@B21]). In particular, we have focused on alterations in the GABA system, and found that GABA~A~ receptors from epileptic tissue (hippocampus and neocortex) become less responsive to repeated activation (as detected by current rundown) than those from healthy tissue ([@B13], [@B14],[@B15]; [@B25]). This use-dependent GABA~A~ receptor desensitization may imply hyper-excitability and favor the occurrence of spontaneous seizures. This phenomenon occurs both in human tissue and in animal models (pilocarpine), becomes detectable in the hippocampus at the time of the first spontaneous seizure and may depend upon alteration in the molecular composition of the GABA~A~ receptor ([@B10]).

Once spontaneous seizures begin to occur and the diagnosis of epilepsy is made, the disease often continues to progress, with increasing severity of seizures; neurological decline and appearance of co-morbidities; development of resistance to pharmacological treatments ([@B22]). Many studies have been performed that provided mechanistic interpretations for the development of pharmaco-resistance. The best-described mechanisms are drug-related, i.e., drug-induced alterations in transport to the CNS (blood--brain barrier crossing) or in pharmacodynamics, which lead to attenuation or loss of therapeutic effects ([@B27]). However, the progression of the disease *per se* may also implicate alterations in the responsiveness to pharmacological agents. Identifying these disease-induced alterations in the response to drugs may provide the basis for more effective treatment strategies in the different phases of mTLE.

To challenge the hypothesis that the disease progression affects drug responsiveness, we explored the sensitivity to pharmacological treatments of the increased rundown of the GABA current (*I*~GABA~) observed in epileptic tissue at different stages of experimental mTLE, namely at the time of the first spontaneous seizure and in the chronic period. We employed two structurally unrelated agents, levetiracetam (LEV) and brain-derived neurotrophic factor (BDNF), because both have been previously demonstrated to be capable of reducing the increased *I*~GABA~ rundown in the human and also in the rat epileptic brain ([@B17], [@B14],[@B15]). Whereas LEV is a clinically employed anti-epileptic drug, BDNF has been reported to provide anti-epileptic effects under some ([@B18]) but not all ([@B5]) experimental conditions and is not in clinical use.

MATERIALS AND METHODS {#s1}
=====================

ANIMALS
-------

Male Sprague-Dawley rats (240--260 g; Harlan, Italy) were used for all experiments. Animals were housed under standard conditions: constant temperature (22--24°C) and humidity (55--65%), 12-h dark--light cycle, and free access to food and water. All efforts were made to minimize animal suffering. Procedures involving animals and their care were carried out in accordance with European Community and national laws and policies (authorization number: D.M. 83/2009-B; 246/2012-13).

PILOCARPINE
-----------

Pilocarpine was administered i.p. (300 mg/kg), and behavior was observed for several hours thereafter. Within the first hour after injection, all animals developed seizures evolving into recurrent generalized convulsions \[status epilepticus (SE); average time between pilocarpine administration and onset of convulsive SE: 19 ± 2\]. SE was interrupted 3 h after onset by administration of diazepam (10 mg/kg i.p). The animals were then assigned to two experimental groups representing different phases of the natural history of the disease: a subgroup was sacrificed 6 h after the first spontaneous seizure; the other subgroup was sacrificed 1 month after SE, i.e., in the chronic period when animals were experiencing an average of 5.3 ± 1.2 spontaneous seizures per day.

Seizures were assessed by 24/24-h, 7/7-day video monitoring, performed using a digital video surveillance system DSS1000 (AverMedia Technologies, USA). Recording electrodes were implanted in the hippocampus and cortex for identification of the first spontaneous seizure \[continuous video-EEG (electroencephalogram) monitoring from day 4 after SE until the day of the first spontaneous seizure\]. EEG seizure were categorized as paroxysmal activity of high frequency (\>5 Hz) characterized by a \>3-fold amplitude increment over baseline ([@B32]; [@B19]). Seizure severity was scored using the scale of [@B24]: (1) chewing or mouth and facial movements; (2) head nodding; (3) forelimb clonus; (4) generalized seizure with rearing; (5) generalized seizure with rearing and falling. Analysis was performed by two independent investigators that were blind for the group to which the rats belonged. In case of differential evaluation, data were reviewed together to reach a consensus ([@B19]). In the chronic period, animals were continuously video recorded for a week before being killed (i.e., 23--30 days after SE), to identify frequency and duration of generalized seizures.

OOCYTES
-------

Membranes were prepared from the hippocampus and the fronto-temporal cortex. Preparation of *Xenopus laevis* oocytes and injection procedures were as previously described in detail ([@B11]). Briefly, tissues were homogenized using a Teflon glass homogenizer with 2 ml of assay buffer of the following composition (in mM): 200 glycine, 150 NaCl, 50 ethylene glycol tetraacetic acid (EGTA), 50 ethylenediaminetetraacetic acid (EDTA), 300 sucrose; 20 μl protease inhibitors (Sigma Aldrich Inc., USA); pH 9 (adjusted using NaOH). The homogenate was centrifuged for 15 min at 9,500 *g*. The supernatant was collected and centrifuged for 2 h at 105 *g* at 4°C. The pellet was washed, re-suspended in 5 mM glycine and used directly, or aliquoted and stored at -80°C for later use. From 12 to 48 h after injection, membrane currents were recorded from voltage-clamped oocytes using two microelectrodes filled with 3 M KCl. The oocytes were placed in a recording chamber (0.1 ml) perfused continuously (9--10 ml/min) with oocyte's Ringer solution (OR) at room temperature (20--22°C). OR had the following composition (in mM): NaCl 82.5, KCl 2.5, CaCl~2~ 2.5, MgCl~2~ 1, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 5, pH 7.4 (adjusted using NaOH). GABA current rundown was defined as the decrease (in percentage) of the current peak amplitude after six 10-s applications of 1 mM GABA at 40-s intervals ([@B14]). The fast *I*~GABA~ desensitization was defined as the time taken for the current to decay from its peak to half-peak value (*T*~0.5~).

Levetiracetam was dissolved in H~2~O and stored as frozen stock solutions (100 mM). BDNF (Sigma) was dissolved in H~2~O, stored as frozen stock solutions (50 μg/ml). Both LEV and BDNF were diluted to working concentrations shortly before the experiments and applied to oocytes for 2 h. In all experiments the holding potential was -60 mV. In some experiments, 3 h washout with OR was performed before initiation of a new rundown protocol.

All drugs were purchased from Sigma except GABA, which was purchased from Tocris (UK). Data in **Figure [1](#F1){ref-type="fig"}** were analyzed for fitting a single exponential curve; data in **Figures [2](#F2){ref-type="fig"}** and **[3](#F3){ref-type="fig"}** were statistically analyzed using analysis of variance (ANOVA) and *post hoc* the Holm--Sidak test (SigmaPlot Software, USA).

![***I*~GABA~ rundown in oocytes injected with rat brain membranes.** **(A)** Time course of current rundown in oocytes injected with hippocampal membranes form control rats (◦), rats killed after the first spontaneous seizure (•), and rats killed in the chronic period, 30 days after SE (□). Peak amplitudes of *I*~GABA~ were normalized to those elicited by the first GABA application (95 ± 20 nA in the control group; 115 ± 21 nA in the first seizure group; 98 ± 18 nA in the chronic group). **(B)** Time course of current rundown in oocytes injected with cortical membranes form control rats (◦), rats killed after the first spontaneous seizure (•), and rats killed in the chronic period, 30 days after SE (□). Peak amplitudes of *I*~GABA~ were normalized to those elicited by the first application (190 ± 25 nA in control; 230 ± 25 nA in first seizure; 201 ± 30 nA in chronic). GABA pulses were 1 mM, 10-s duration every 40 s. Data are means ± SEM (*n* = 12). All data sets fitted to an exponential curve.](fncel-07-00108-g001){#F1}

![**Effect of BDNF on *I*~GABA~ run-down from oocytes injected with membranes prepared from rats killed at various time points after pilocarpine-induced SE.** **(A)** Representative superimposed currents elicited by the first and sixth GABA application (1 mM, horizontal bar) in oocytes injected with hippocampal or cortical membranes prepared from rats killed 6 h after the first spontaneous seizure, in the presence or absence of 0.5 μg/ml BDNF, as indicated. *I*~GABA~ rundown in oocytes injected with hippocampal **(B)** or cortical **(C)** membranes, in the absence or in the presence of BDNF, as indicated. Data in **(B,C)** are the means ± SEM of 15--36 oocytes per group (three to four rats; nine frogs). *I*~GABA~ peak values were normalized to the first *I*~GABA~ peak current amplitude. Holding potential, -60 mV. \**P* \< 0.05 vs. control values, ANOVA and *post hoc* Holm--Sidak test.](fncel-07-00108-g002){#F2}

![**Effect of levetiracetam (LEV) on *I*~GABA~ run-down from oocytes injected with membranes prepared from rats killed at various time points after pilocarpine-induced SE.** **(A)** Representative superimposed currents elicited by the first and sixth GABA application (1 mM, horizontal bar) in oocytes injected with hippocampal or cortical membranes prepared from rats killed 6 h after the first spontaneous seizure, in the presence or absence of 1 μM LEV, as indicated. *I*~GABA~ rundown in oocytes injected with hippocampal **(B)** or cortical **(C)** membranes, in the absence or in the presence of LEV, as indicated. Data in **(B,C)** are the means ± SEM of 9--25 oocytes per group (three to four rats; nine frogs). *I*~GABA~ peak values were normalized to the first *I*~GABA~ peak current amplitude. Holding potential, -60 mV. \**P* \< 0.05 vs. control values, ANOVA and *post hoc* Holm--Sidak test.](fncel-07-00108-g003){#F3}

RESULTS
=======

In agreement with previous reports ([@B15]; [@B10]) applications of 1 mM GABA to oocytes injected with membranes from the cortex and hippocampus elicited inward currents that were sensitive to 100 μM bicuculline (not shown). Depending on the oocytes, the frogs and the rats, *I*~GABA~ currents had variable amplitudes: some were as large as -250 nA, others as small as -10 nA. These currents exhibited rundown after repetitive GABA applications: *I*~GABA~ elicited by the sixth GABA application fell to 69.4 ± 3 and 68.6 ± 4% of the one elicited by the first GABA application in oocytes injected with cortical and hippocampal membranes, respectively (mean ± SEM of 3 rats, 9 frogs, 49 oocytes). As previously described ([@B10]), *I*~GABA~ rundown was increased in membranes prepared from epileptic rats at the time of the first spontaneous seizure in the hippocampus (fall to 45.7 ± 3%; range 14--62%; *P* \< 0.01) but not in the cortex (fall to 73.8 ± 4%; range 43--113%; **Figure [1](#F1){ref-type="fig"}**). Again consistent with previous reports ([@B10]), *I*~GABA~ rundown was significantly increased both in the hippocampus (44.5 ± 3%; range 20--62%; *P* \< 0.01) and in the cortex (41 ± 4%; range 15--54%; *P* \< 0.01) of in membranes prepared from chronic animals (**Figure [1](#F1){ref-type="fig"}**). This current rundown was not accompanied by a significant change in current decay and it was partially reversible after 15--20 min of washout (not shown), as previously shown in human brain tissue ([@B13]; [@B25]).

Application of the neurotrophic factor BDNF abolished the increase in *I*~GABA~ rundown associated with epilepsy. Indeed, in oocytes injected with hippocampal membranes, 2-h incubation with 0.5 μg/ml BDNF decreased *I*~GABA~ rundown both in the first seizure (65.3 ± 3%) and in the chronic epilepsy group (68 ± 4%; **Figures [2A](#F2){ref-type="fig"},[B](#F2){ref-type="fig"}**). Moreover, BDNF abolished the increased *I*~GABA~ rundown in oocytes injected with cortical membranes from chronic animals (61 ± 2%), whereas it did not influence the small *I*~GABA~ rundown in first seizure animals (72.6 ± 5% **Figures [2A](#F2){ref-type="fig"},[C](#F2){ref-type="fig"}**).

The pattern of LEV effects dramatically differed from the one of BDNF. LEV (1 μM) did not affect rundown in the hippocampus, neither in control nor in epileptic tissues (48.8 ± 3 and 49.0 ± 7%, first seizure and chronic animals, respectively; **Figures [3A](#F3){ref-type="fig"},[B](#F3){ref-type="fig"}**), but significantly attenuated it in the epileptic cortex (91.0 ± 5 and 78.0 ± 4%, first seizure and chronic animals, respectively; **Figures [3A](#F3){ref-type="fig"},[C](#F3){ref-type="fig"}**). It is noteworthy that BDNF and LEV shared the same effect in decreasing *I*~GABA~ rundown only in the cortex from chronic animals. This effect was not linked to a change in the current decay (*T*~0.5~ = 9.0 ± 2.0 s in untreated cortical membranes; 8.4 ± 1.5 s with BDNF; 8.7 ± 1.0 s with LEV; *P* \> 0.05).

DISCUSSION
==========

MAIN FINDINGS
-------------

We found here that: (1) an increased *I*~GABA~ rundown is observed in the hippocampus but not in the cortex at the time of the first spontaneous seizure, whereas it is observed in both brain areas in the chronic period; (2) the neurotrophic factor BDNF abolishes this increased rundown in the hippocampus at the time of the first seizure, as well as in the hippocampus and cortex in the chronic period; (3) LEV does not affect rundown in the hippocampus, but attenuates it in the cortex. Below, we will discuss the possible mechanisms by which BDNF and LEV may affect *I*~GABA~ current rundown, that is, use-dependent GABA~A~ receptor desensitization; we will propose mechanisms that may underlie the alterations in rundown intensity and sensitivity to drugs during the progression of epilepsy; we will examine the implications of these findings.

BRAIN-DERIVED NEUROTROPHIC FACTOR
---------------------------------

The effects of BDNF in epilepsy are still controversial ([@B29]). Whereas some studies support a proepileptogenic role ([@B5]), BDNF has also been reported to exert beneficial effects based on its neuroprotective and/or neurogenic actions ([@B18]). The anti-rundown effects of BDNF reported here confirm a previous report ([@B15]) and suggest an anti-seizure potential. However, it is unclear why BDNF, at variance with LEV, can prevent increased GABA~A~ receptor rundown in all epileptic tissue that exhibit it, hippocampus or cortex, but does not affect rundown in normal tissue (importantly, this has been also observed in the human tissue; [@B17]). A working hypothesis may be that this is due to modulatory effects on GABA~A~ receptor subunits expressed in the epileptic (but not as much in the normal) hippocampus and cortex.

The molecular mechanisms underlying the increased rundown in the epileptic tissue are still unknown. However, it has been hypothesized that they depend on alterations in GABA~A~ receptor subunit composition ([@B10]). Indeed, changes in the expression levels (thus, in the expected molecular composition) of GABA~A~ receptors have been described in epilepsy models and in the human epileptic tissue. Increased expression of the α 4 subunit has been reported in many studies, whereas the α 1 subunit has been reported to be slightly increased, unaltered, or even decreased ([@B2]; [@B31]; [@B20]; [@B30]). Therefore, a shift in balance toward an increase in the relative representation of α 4- compared with α 1-containing GABA~A~ receptors has been proposed, and is supported by initial immunohistochemical evidence ([@B10]). This alteration should be proepileptic because (1) the α 1 subunit is significantly more expressed in animals less susceptible to seizures, like immature ([@B34]) or slow kindling rats ([@B23]); (2) viral vector-mediated correction of the reduced α 1/α 4 ratio inhibits epilepsy development ([@B26]). Moreover, α 4-containing GABA~A~ receptors exhibit reduced response to repetitive GABA application, i.e., increased rundown ([@B6]).

It has been suggested that BDNF may favor increased α 4 gene expression and/or decreased α 1 gene expression ([@B1]). However, these effects should be pro-epileptic and, therefore, could not account for those observed in the present study. One alternative hypothesis may be based on protein kinase C (PKC) activation. It has been proposed that the abnormal GABA current run-down is caused by receptor de-phosphorylation ([@B13]) and that BDNF modulation of GABA rundown is PKC-dependent ([@B16]). Based on these data, it may be hypothesized that BDNF corrects GABA~A~ receptor malfunction phosphorylating GABA subunits whose expression is altered in epilepsy, like the α 1 and the α 4, but also the δ or the γ2. Expression of the δ subunit has been reported to be consistently reduced in granule cell dendrites ([@B28]; [@B31]; [@B12]), and the δ subunits may be replaced by γ2 , resulting in impairment of both tonic and phasic GABA transmission ([@B35]).

LEVETIRACETAM
-------------

Levetiracetam is a widely used antiepileptic drug that also has utility in migraine prophylaxis ([@B8]; [@B4]). Despite its efficacy, there is no well-accepted mechanism that explains the antiepileptic action of LEV. It is well known that LEV binds to the presynaptic protein SV2A, indicating a role in vesicle exocytosis ([@B9]). Because SV2A is implicated in maintaining the size of the readily releasable pool of synaptic vesicles ([@B3]), LEV has been suggested to directly inhibit presynaptic neurotransmitter release ([@B33]). In addition, however, PKC inhibitors have been found to block LEV effects on GABA rundown, indicating a role for PKC in LEV action ([@B14]). LEV has been also reported to increase ROMK1 channel activity in a PKA-dependent manner ([@B7]). PKC-mediated phosphorylation of GABA~A~ receptors (with decreased rundown) and PKA-mediated phosphorylation of the ROMK1 channels (with stabilization of the resting membrane potential) may both contribute to the anti-epileptic effects of LEV, which would therefore include both a pre-synaptic (SV2A) and a post-synaptic (PKC- and PKA-dependent) component. Of course the latter and not the former may be implicated in the effect on *I*~GABA~ current rundown observed in this study.

It still remains to be determined why LEV does not reduce GABA~A~ receptor rundown in the hippocampus, whereas it reduces it in the epileptic neocortex even when it is not yet increased by the disease progression, i.e., at the time of the first spontaneous seizure. A working hypothesis may be that this is due to phosphorylation of one or more GABA~A~ subunits differentially expressed between the epileptic cortex and hippocampus. These subunit(s) should be expressed even before increased rundown is detectable in the cortex and should be different from the one that is putatively targeted by BDNF. *Ad hoc* studies should be performed to challenge this hypothesis. In any event, it is noteworthy that, in a previous work in human mTLE, LEV did not affect subicular GABA~A~ receptors whereas it profoundly influenced the cortical ones ([@B14]), supporting the present finding that LEV effects are brain region specific.

In summary, it may be hypothesized that BDNF exerts its effects by phosphorylation of GABA subunits specifically expressed in the epileptic brain, while LEV may act on other subunit(s) that are specific to the epileptic cortex. Moreover, LEV reduces rundown in the cortex even before it is increased in the chronic epileptic period, whereas BDNF can only abolish disease-associated increases in *I*~GABA~ rundown. These observations implicate differences in efficacy on the control of seizures of different anatomical origin or occurring at different stages in the natural history of mTLE.

CONCLUSION
==========

In this study, we challenged the hypothesis that the disease progression affects drug responsiveness by examining the sensitivity to pharmacological treatments of the increased *I*~GABA~ rundown in the epileptic hippocampus and cortex at different stages of experimental mTLE. The data suggest that the sensitivity of GABA~A~ receptors to pharmacological interventions undergoes changes during the natural history of mTLE, implicating that site of seizure initiation and the timing of treatment may highly affect the therapeutic outcome. Further studies will be needed to better validate this hypothesis and to characterize its mechanism. These will include testing other drugs for their ability to modulate rundown in the different regions and at the different time-points, as well as analyzing the alterations in GABA receptor subunit composition during epilepsy development and correlating it with rundown. Importantly, part of these experiments is amenable to verification in the human tissue. If successful, these studies may lead to new and more effective therapies.
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